Pseudoginsenoside RT4
Based on 1 Customer Validation
Pseudoginsenoside RT4 is an orally active anti-inflammatory agent. Pseudoginsenoside RT4 can be isolated from Panax pseudoginseng subsp. Himalaicus, Panax vietnamensis Ha et Grushv, and Panax quinquefolius L. Pseudoginsenoside RT4 reduces the levels of TNF-α, IL-6, and IL-1β, elevates the level of IL-10, improves the histopathological features of colon tissue, maintains the ultrastructure of colonic epithelium, protects the integrity of cell monolayers, increases the expression of tight junction proteins, raises the total content of short-chain fatty acids, corrects intestinal flora disorder, reduces the disease activity index score, restores colon length, and decreases the spleen index. Pseudoginsenoside RT4 exhibits hepatoprotective effects. Pseudoginsenoside RT4 can be used in studies related to ulcerative colitis.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度 : 97.05%
- CAS 番号: 98474-77-2
- 分子式: C36H62O10
- 分子量:654.87
-
保管条件:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
生物活性
製品説明
IC50 & Target
[1]|
IL-6 |
IL-1β |
IL-10 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| Hepatocyte | IC50 |
74.8 μM
Compound: 4
|
Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs
Hepatoprotective activity in mouse hepatocytes assessed inhibition of D-galactosamine/TNFalpha-induced cell death dosed administered before 30 mins of TNFalpha challenge measured after 18 hrs
|
[PMID: 11325227] |
体外実験
Pseudoginsenoside RT4 (4-16 µg/mL; 18 h) protects LPS-induced Caco-2 cell epithelial barrier damage by down-regulating pro-inflammatory cytokines, increasing TEER values, and enhancing tight-junction protein expression, with the strongest effects seen at 16 µg/mL[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Caco-2
-
Concentration:4-16 µg/mL (anti-inflammatory/barrier protection assay); 0-64 µg/mL (cell viability assay)
-
Incubation Time:18 h (anti-inflammatory/barrier protection assay); 4 h (cell viability assay)
-
Result:Maintained cell viability above 80% at 4, 8, and 16 µg/mL.
Dose-dependently down-regulated levels of pro-inflammatory factors TNF-α, IL-6, and IL-1β.
Significantly reduced all three pro-inflammatory factors at 8 and 16 µg/mL.
Specifically reduced IL-6 levels at 4 µg/mL.
Increased TEER values compared to the LPS-induced model group at 16 µg/mL.
Dose-dependently increased the expression and restored the membrane distribution of tight-junction proteins ZO-1, occludin, claudin-1, and E-cadherin at 4, 8, and 16 µg/mL.
Parmacokinetics
| Species | Dose | Route | AUC0-t | AUC0-∞ | T1/2 | Tmax | Vd | CL | Cmax | Bioavailability |
|---|---|---|---|---|---|---|---|---|---|---|
| Mice[1] | 10 mg/kg | i.g. | 991.55 h·μg/L | 1139.92 h·μg/L | 4.67 h | 1.50 h | 61.91 L/kg | 9.12 L/h/kg | 165.13 μg/L | / |
| Mice[1] | 20 mg/kg | i.g. | 2438.90 h·μg/L | 2698.59 h·μg/L | 6.29 h | 1.17 h | 71.24 L/kg | 8.04 L/h/kg | 295.59 μg/L | / |
| Mice[1] | 40 mg/kg | i.g. | 5288.20 h·μg/L | 5993.63 h·μg/L | 7.17 h | 1.33 h | 71.60 L/kg | 7.20 L/h/kg | 658.65 μg/L | 18.90 % |
| Mice[1] | 2 mg/kg | i.v. | 1246.37 h·μg/L | 1380.43 h·μg/L | 2.24 h | 0.03 h | 4.57 L/kg | 1.51 L/h/kg | 1970.34 μg/L | / |
体内実験
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Balb/c (male, 6-7-week-old, DSS-induced ulcerative colitis)[1]
-
Dosage:10 mg/kg; 20 mg/kg; 40 mg/kg
-
Administration:i.g.; daily; 3 days
-
Result:Reduced disease activity index (DAI) scores at 20 mg/kg and 40 mg/kg doses.
Increased body weight compared to the model group at 40 mg/kg dose.
Lengthened colon length at 20 mg/kg and 40 mg/kg doses; showed no statistically significant effect on colon length at 10 mg/kg dose.
Lowered spleen index in a dose-dependent manner across all three doses.
Decreased levels of pro-inflammatory cytokines TNF-α, IL-6, and IL-1β in serum and colon, and increased levels of anti-inflammatory cytokine IL-10 in serum and colon at 40 mg/kg dose.
Decreased levels of TNF-α, IL-6, and IL-1β in serum and colon, and increased colon IL-10 levels at 20 mg/kg dose.
Decreased levels of TNF-α, IL-6, and IL-1β in colon tissue at 10 mg/kg dose.
Restored total short-chain fatty acid (SCFA) content in cecal contents toward normal levels across all three doses.
Improved colonic histopathology in a dose-dependent manner: partially restored colonic crypt structure and reduced inflammatory infiltration at 10 mg/kg dose; clearly restored crypt structure and quantity and reduced inflammation at 20 mg/kg dose; restored crypt structure and quantity to near-normal levels with minimal inflammatory cell infiltration at 40 mg/kg dose.
Restored the ultrastructure of colonic mucosal epithelial cells in a dose-dependent manner, with 40 mg/kg dose maintaining near-normal microvilli arrangement and no organelle degeneration.
Increased gut microbiota operational taxonomic unit (OTU) count from 4677 (model group) to 7228, restored Shannon index to near-normal levels, and shifted gut microbiota structure toward that of normal mice at 40 mg/kg dose.
Normalized phylum-level abundances (reduced Acidobacteria, Proteobacteria, Epsilonbacteraeota, Actinobacteria; increased Tenericutes, Bacteroidetes) and genus-level abundances (reduced Escherichia-Shigella, Bacteroides; increased Alloprevotella, Rikenellaceae RC9 gut group, Odoribacter, Alistipes, Lactobacillus) at 40 mg/kg dose.
化学情報
-
CAS 番号 98474-77-2
-
性状 Solid
-
分子量 654.87
-
分子式 C36H62O10
-
Color White to off-white
-
SMILES
C[C@]12[C@]3([C@@]([C@@H](C[C@]1([H])[C@@]4([C@@](C(C)([C@H](CC4)O)C)([H])[C@H](C2)O[C@@H]5O[C@@H]([C@H]([C@@H]([C@H]5O)O)O)CO)C)O)([H])[C@]([C@]6(O[C@@H](CC6)C(C)(O)C)C)([H])CC3)C
-
Structure Classification
-
Initial Source
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
プロトコル
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
DSS-Induced Colitis
Dextran sulfate sodium (DSS)-induced colitis is generated by administering DSS in mouse drinking water, producing epithelial injury, barrier disruption, weight loss, diarrhea, fecal blood, colon shortening, histologic mucosal damage, and inflammatory mediator changes; the model is mainly used to study acute or chronic intestinal inflammation resembling selected features of ulcerative colitis. DSS injury is interpreted through clinical and tissue readouts rather than a single molecular endpoint: daily body weight, stool consistency, and bleeding are combined into a disease activity index, while colon length, histology, cytokines, myeloperoxidase activity, intestinal permeability, and tight-junction markers provide complementary measures of inflammation and barrier damage.
-
TNBS-Induced Colitis
TNBS-induced colitis is produced by intrarectal delivery of 2,4,6-trinitrobenzene sulfonic acid in ethanol, where ethanol disrupts the mucosal barrier and TNBS haptenates colonic proteins, generating immune-mediated colonic inflammation with weight loss, diarrhea, ulceration, transmural injury, inflammatory-cell infiltration, and cytokine responses. The model is used as an experimental intestinal inflammation model with Crohn’s disease–like features, especially when Th1-type responses, IL-12–dependent inflammation, chronic relapsing inflammation, or fibrosis-related endpoints are studied.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
-
Pyroptosis Solutions
Pyroptosis is a lytic inflammatory cell-death pathway executed by gasdermin pores, most classically through inflammasome-mediated activation of caspase-1, cleavage of gasdermin D, membrane pore formation, LDH release, and secretion of IL-1β and IL-18. The canonical pathway is commonly modeled by priming cells with an inflammatory signal such as LPS to induce pro-IL-1β and inflammasome components, followed by an activation signal such as ATP or nigericin to activate NLRP3, ASC speck formation, caspase-1 cleavage, GSDMD cleavage, cytokine release, and pyroptotic membrane rupture. The non-canonical pathway is triggered when cytosolic LPS activates mouse caspase-11 or human caspase-4/5, leading to GSDMD cleavage and pyroptosis, and this can secondarily activate NLRP3-dependent IL-1β release. Pyroptosis is linked to inflammatory injury, infection, cancer, liver disease, ocular disease, placental inflammation, and other disease phenotypes, but unresolved questions include which gasdermin fam
純度とドキュメンテーション
-
データシート (296 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)